SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare jumps after its arm enters into BTA with Zenex Animal Health

12 May 2021 Evaluate

Cadila Healthcare is currently trading at Rs. 645.45, up by 15.75 points or 2.50% from its previous closing of Rs. 629.70 on the BSE.

The scrip opened at Rs. 634.95 and has touched a high and low of Rs. 673.70 and Rs. 632.80 respectively. So far 848084 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 321.30 on 13-May-2020.

Last one week high and low of the scrip stood at Rs. 673.70 and Rs. 592.95 respectively. The current market cap of the company is Rs. 66661.00 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 16.53% and 8.40% respectively.

Cadila Healthcare’s wholly owned material subsidiary -- Zydus Animal Health and Investment (ZAHL) has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements (together Definitive Agreements) for disposal of its Animal Healthcare Established Markets Undertaking  (having animal healthcare business in India and certain other countries) to Zenex Animal Health India (formerly known as Nutrizvit Animal Health India), by way of a slump sale, without values being assigned to the individual assets and liabilities on debt free and cash free basis, subject to certain closing date adjustments specified in the BTA, with effect from such date, in such manner and on such terms and conditions, as specified in the Definitive Agreements.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

956.65 17.75 (1.89%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×